Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398008 | 0.80 | HTR2A (0.34) | HTR2AHTR2CHTR2BDRD2DRD4 | |
| SCHEMBL19461932 | 0.77 | MEN1 (0.39) | NPC1RAB9ASMN1; SMN2ESR1NUDT1 | |
| SCHEMBL16398232 | 0.75 | NPC1 (0.33) | NPC1RAB9ASMN1; SMN2ESR1 | |
| SCHEMBL16398389 | 0.74 | HTR2A (0.34) | HTR2AHTR2CHTR2BFFAR4 | |
| SCHEMBL16397920 | 0.72 | CHRM3 (0.37) | HTR2AHTR2CHTR2BDRD2DRD4 | |
| SCHEMBL16398386 | 0.72 | HTR2A (0.31) | HTR2AHTR2CHTR2BDRD2DRD4 | |
| SCHEMBL27859177 | 0.72 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2ESR1 | |
| SCHEMBL16398384 | 0.71 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL23588568 | 0.71 | ESR1 (0.40) | NPC1RAB9ASMN1; SMN2ESR1NUDT1 | |
| SCHEMBL16398055 | 0.69 | IDH1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004079-B1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | ACTURUM REAL ESTATE AB (SE) | 2018-01-17 | — | — | EP | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-9439904-B2 | Pyrimidine compounds and their use as gamma secretase modulators | Acturum Life Science AB (SE) | 2016-09-13 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-05-12 | — | — | US | disclosed |
| EP-3004079-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014195323-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | Acturum Life Science AB (SE) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129002-A1 | PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, APP | HTR2A 2603/4885HTR2C 3436/4885HTR2B 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.